Skip to content

Tumor-infiltrating CD8+ T-cell count in fluid (e.g., pleural effusion, ascites)

Published: August 9, 2026Updated: August 16, 2026

This test measures the number of CD8+ T-cells—an important type of immune cell—found in a sample of body fluid, such as fluid collected from around the lungs (pleural effusion) or abdomen (ascites). These cells play a key role in fighting cancer.

Quick summary

["Assesses immune cell activity in fluid samples for cancer monitoring or diagnosis."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
60578-2
Short code
TCRG gene Rear Fld Ql
Synonyms
TCRG gene Rear Fld Ql
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
molgen
CPT
86430
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your doctor may recommend this test if you have a condition involving abnormal fluid buildup, such as pleural effusion or ascites, and suspect cancer. It helps evaluate whether cancer cells are present and how the immune system is responding in that fluid.

What to Expect Before the Test

No special preparation is typically needed. The fluid sample may be collected through a procedure like a thoracentesis (for pleural fluid) or paracentesis (for abdominal fluid). You may experience mild discomfort, but it’s usually brief.

What the Test Results Mean

Results show the count of CD8+ T-cells in the fluid sample. Higher counts may indicate an active immune response, while very low counts could suggest immune suppression or cancer presence. Your doctor will interpret results in the context of your overall health and medical history.

Common Uses and Conditions

This test is often used in oncology to monitor treatment response, assess cancer spread, or evaluate immune activity in fluid collections. It may also help guide decisions about further cancer therapies.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical significance: Elevated CD8+ T-cell counts in body fluids can signal an immune response to cancer, potentially indicating early tumor detection or a positive response to treatment. Low counts may suggest cancer progression, immune dysfunction, or other underlying conditions requiring further investigation.

Short name

CD8+ T-cell count in body fluid

Frequently asked questions

What does a high or low CD8+ T-cell count in fluid mean?
A high count may indicate an active immune response to cancer or other infections, while a low count could suggest cancer progression, immune suppression, or other factors affecting your body’s ability to fight infections.
Does this test require fasting?
No fasting is required for this test. The sample is collected from fluid, not blood or urine, so diet or timing does not affect the results.
How long will it take to get results?
Results are typically available within a few days to a week, depending on lab processing and your healthcare provider’s workflow. Your doctor will discuss findings with you during your follow-up visit.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy